Fusion Pharmaceuticals News

RBC Capital Remains a Hold on Fusion Pharmaceuticals (FUSN)

TipRanksMay 8 18:37

Fusion Pharmaceuticals Analyst Ratings

BenzingaApr 16 19:51

Fusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data

TipRanksApr 12 13:37

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Fusion Pharmaceuticals (FUSN)

TipRanksApr 10 19:30

Fusion Pharmaceuticals Analyst Ratings

BenzingaMar 21 22:58

Fusion Pharmaceuticals Analyst Ratings

BenzingaMar 20 19:25

Fusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market Dynamics

TipRanksMar 20 20:06

Fusion Pharmaceuticals (FUSN) Was Downgraded to a Hold Rating at JonesTrading

TipRanksMar 20 04:25

Jefferies Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $10

MT NewswiresMar 20 02:39

Morgan Stanley Downgrades Fusion Pharmaceuticals to Equalweight From Overweight, Raises Price Target to $21 From $10

MT NewswiresMar 20 02:38

Fusion Pharmaceuticals: Hold Rating Affirmed Post-AstraZeneca Acquisition Announcement

TipRanksMar 20 00:05

Truist Securities Downgrades Fusion Pharmaceuticals to Hold From Buy, Adjusts Price Target to $21 From $11

MT NewswiresMar 20 00:04

Fusion Pharmaceuticals Analyst Ratings

BenzingaMar 19 23:54

Truist Securities Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21

BenzingaMar 19 23:56

Raymond James Downgrades Fusion Pharmaceuticals to Market Perform From Strong Buy, Raises Price Target to $21 From $16

MT NewswiresMar 19 23:05

Brookline Capital Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $20

MT NewswiresMar 19 22:58

Wedbush Downgrades Fusion Pharmaceuticals to Neutral, Announces $24 Price Target

BenzingaMar 19 22:20

Fusion Pharmaceuticals: Hold Rating Amid AstraZeneca Acquisition and Radiopharmaceutical Prospects

TipRanksMar 19 22:15

Fusion Pharmaceuticals Analyst Ratings

BenzingaMar 19 19:14

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)

TipRanksMar 19 18:30